8-K: Celcuity Submits FDA Application for REVTORPYK in Breast Cancer

Celcuity Inc. announced the submission of a supplemental New Drug Application (sNDA) to the FDA for REVTORPYK (gedatolisib) for a specific subset of advanced breast cancer patients.

Summary

• Celcuity Inc. has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for its drug REVTORPYK (gedatolisib).
• The sNDA seeks approval for REVTORPYK in treating patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (ABC) who have a PIK3CA mutation and have progressed after at least one line of endocrine therapy.
• This submission follows a previous FDA approval of REVTORPYK on July 14, 2026, for patients with HR+/HER2ABC without a PIK3CA mutation.
• The application is supported by positive results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, indicating significant progress in the company's drug development pipeline and potential for expanded market access.

Positives

• Submission of sNDA to FDA for REVTORPYK in a new patient population (PIK3CA mutant).
• Positive results from the Phase 3 VIKTORIA-1 trial supporting the sNDA.
• REVTORPYK plus fulvestrant and palbociclib reduced the risk of disease progression or death by 50% in the PIK3CA mutant cohort compared to alpelisib plus fulvestrant.
• Median progression-free survival (PFS) was 11.1 months with the REVTORPYK-triplet versus 5.6 months with alpelisib plus fulvestrant.
• REVTORPYK plus fulvestrant showed a 49% reduction in the risk of disease progression or death.
• Median PFS for the REVTORPYK-doublet was 11.3 months versus 5.6 months.
• Robust and durable responses observed: 49% objective response rate (ORR) for the triplet and 36% ORR for the doublet.
• The company aims to make REVTORPYK available to a broader population of patients.

Negatives

• The drug has potential for severe stomatitis (72% incidence in triplet arm), rash (40% incidence in doublet arm), and hyperglycemia (57% incidence in doublet arm).
• REVTORPYK can cause fetal harm and requires effective contraception for both males and females of reproductive potential.
• The safety of REVTORPYK has not been established in patients with Type 1 or uncontrolled Type 2 diabetes mellitus.

Risks

• Potential for unforeseen delays in the FDA's review of the sNDA.
• Market acceptance of REVTORPYK in the PIK3CA mutant population.
• Development of competitive therapies.
• The company's ability to access capital on favorable terms.
• Clinical trial results are based on ongoing analysis and may change upon more comprehensive review.
• Potential for adverse events such as stomatitis, rash, and hyperglycemia requiring dose modifications or discontinuation.

Future Outlook

The company is seeking FDA approval for REVTORPYK in an expanded indication for PIK3CA-mutated advanced breast cancer, aiming to make the treatment available to a broader patient population. The company also has ongoing clinical trials for REVTORPYK in other indications and is focused on its strategy, marketing, and commercialization plans.

Management Comments

• "This submission allows us to potentially make REVTORPYK available to all patients with HR+/HER2locally advanced or metastatic breast cancer, regardless of PIK3CA mutation status," said Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity.
• "In the PIK3CA mutant cohort of the VIKTORIA-1 trial, REVTORPYK demonstrated compelling safety and efficacy results. Pending regulatory approval, we believe REVTORPYK has the potential to become an important treatment option in this indication."
• "The recent FDA approval of REVTORPYK marked an important milestone for Celcuity and for patients with PIK3CA wild-type HR+/HER2advanced breast cancer," said Brian Sullivan, CEO and co-founder of Celcuity.
• "We are deeply committed to expanding the availability of REVTORPYK to a broader population of patients. We look forward to working collaboratively with the FDA on this application to potentially bring this treatment to patients with PIK3CAmutated locally advanced or metastatic breast cancer."

Industry Context

StockSavvy.ai notes that the submission of this sNDA by Celcuity Inc. aligns with the industry trend of developing targeted therapies for specific genetic mutations in cancer, such as PIK3CA mutations in breast cancer. The company's focus on pan-PI3K and mTOR inhibition positions it within a competitive but evolving landscape of oncology treatments.

Stakeholder Impact

• Shareholders: Potential for increased market share and revenue if the sNDA is approved, positively impacting stock value.
• Patients: Expanded treatment options for advanced breast cancer patients with PIK3CA mutations, potentially improving outcomes.
• Healthcare Providers: Introduction of a new treatment option for a specific patient subgroup, requiring understanding of its efficacy and safety profile.
• FDA: Review of the sNDA, a critical step in the drug approval process.

Next Steps

• FDA review of the sNDA for REVTORPYK for PIK3CA mutant breast cancer.
• Potential commercialization of REVTORPYK for the PIK3CA mutant patient population.
• Continued development and evaluation of REVTORPYK in other indications, including metastatic castration-resistant prostate cancer.
• Enrollment and evaluation in ongoing Phase 3 trials (VIKTORIA-2).

Key Dates

Recommendation

The filing represents a significant step forward with the sNDA submission for an expanded indication of REVTORPYK, supported by strong clinical data. However, the ultimate impact on the stock price hinges on FDA approval, market adoption, and the company's ability to manage potential risks and competition. While positive, it warrants a 'hold' to await further regulatory decisions and commercial performance.

Keywords

REVTORPYK, gedatolisib, breast cancer, PIK3CA mutation, metastatic breast cancer, FDA submission, sNDA, VIKTORIA-1 trial